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Abstract
Platelets closely interface with the immune system to fight pathogens, target wound sites, and regulate tissue repair. Natural
platelet levels within the body can be depleted for a variety of reasons, including excessive bleeding following traumatic injury, or
diseases such as cancer and bacterial or viral infections. Platelet transfusions are commonly used to improve platelet count and
hemostatic function in these cases, but transfusions can be complicated by the contamination risks and short storage life of
donated platelets. Lyophilized platelets that can be freeze-dried and stored for longer periods of time and synthetic platelet-
mimetic technologies that can enhance or replace the functions of natural platelets, while minimizing adverse immune responses
have been explored as alternatives to transfusion. Synthetic platelets typically comprise nanoparticles surface-decorated with
peptides or ligands to recreate specific biological characteristics of platelets, including targeting of wound and disease sites and
facilitating platelet aggregation. Recent efforts in synthetic platelet design have additionally focused on matching platelet shape
and mechanics to recreate the marginalization and clot contraction capabilities of natural platelets. The ability to specifically tune
the properties of synthetic platelet-mimetic materials has shown utility in a variety of applications including hemostasis, drug
delivery, and targeted delivery of cancer therapeutics.
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Introduction
Platelets provide several key functions during the process of
hemostasis and tissue repair including targeting wound
sites, facilitating hemostasis, and modulating the repair
and regeneration process following injury. In addition to
their role in hemostasis, platelets play a large role in the
body’s innate immune response to pathogens and other
contaminants. Furthermore, platelets also interface with
cancer cells and have been shown to contribute to cancer
metastasis. The development of non-immunogenic platelet-
mimetic technologies has the potential to greatly improve
treatment of bleeding and may also have significant poten-
tial for targeted drug delivery for treatment of cardiovascu-
lar disease and cancer. Recently, researchers have used
various platelet-mimetic strategies for such applications.
In this review, we present an overview of platelet biology
and immune-related functions, and then discuss recent pla-
telet-mimetic strategies. Finally, we discuss how these stra-
tegies allow for the design of materials that interface with
the immune system.
Platelets in coagulation and hemostasis
Platelets are small, anuclear blood cells that play a primary
role in coagulation and hemostasis following tissue injury.
Platelets are derived from megakaryocytes, which become
polyploid and form a demarcation membrane system
(DMS) as they mature. This DMS allows for storage of
membranes that can be released into proplatelet protrusions
that then develop into mature platelets upon release and
circulation through the bloodstream.1,2 Their unique struc-
tural and biological components enable platelets to promote
hemostasis and wound repair following injury (Figure 1).
Platelets circulate in an inactive state; following initiation of
the coagulation cascade, platelets become active, which
stimulates adhesion of platelets to the injured vessel wall,
platelet aggregation, and release of growth factors from
platelet granules. In their inactive, or quiescent, state, plate-
lets are stiffer than red blood cells. This stiffness causes
them to be pushed towards the vessel wall during circula-
tion in a process known as margination, which in turn gives
them the proximity necessary to interact with and aggregate
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at injury sites along vascular vessel walls.3–5 Upon activa-
tion, platelets undergo a shape change, deform extensively
and ‘‘spread’’ along the vascular wall at injury sites.3 The
thrombogenic properties of endothelial collagen and the
hemostatic behavior of natural platelets interact to form
the basis for the hemostatic activity and clot contraction
that occurs at the vascular wall.3,6
Hemostasis occurs in two phases, known as primary and
secondary hemostasis. During primary hemostasis, plate-
lets target and aggregate at the injury site to form a
‘‘plug’’ of sorts.7 Platelets bind to exposed sub-endothelial
collagen at the injury site via the von Willebrand factor
(VWF), which is released from the Weibel–Palade bodies
of injured vessel walls.8 The A1 domain of the secreted
VWF interacts with GPIba, a ligand-binding protein
within the glycoprotein GP-Ib-V-IX complex on the plate-
let’s surface, allowing the platelets to adhere to the
damaged vascular wall.9–11 GPIba also allows platelets to
activate under high-shear conditions, which facilitates
platelet aggregation at wound sites.10 The activated plate-
lets then spread along the wall and adhere to each other,
forming a platelet plug to stem initial blood loss. Secondary
hemostasis is characterized by the activation of the
blood coagulation cascade and results in the formation
Figure 1 Schematic overview of natural platelet functions and synthetic strategies for mimicking those functions, including shape change following activation (a),
adhesion to injured vascular endothelium (b), aggregation (c), participation in secondary hemostasis (d), and interactions with foreign entities, such as cancer cells,
bacteria and viruses (e). (a) When natural platelets become activated, they change shape and marginate towards vessel walls, where they can adhere and carry out
hemostatic functions. One strategy for platelet-mimetic technologies is to create particles that can match this ability to change shape and carry out margination by
utilizing particles that match the shape and mechanics of platelets. (b–d) Conjugating vWF, collagen-binding motifs, and/or fibrinogen to particles provides another
strategy for mimicking natural platelet activity; the coupled proteins/binding motifs allow the particles to mimic platelet features such as targeting and aggregation at
injury sites and participation in both primary and secondary hemostasis. (e) Platelet-mimetic technologies can also be used to mimic the immune functions of natural
platelets. This has been achieved via heteromultivalent ligand coupling, which allows the particles to target pathogens or diseased cells, and through membrane
cloaking in which drug delivery vehicles are encased in natural platelet membranes, allowing for targeted drug delivery with minimal immune responses. (A color version
of this figure is available in the online journal.)
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of a fibrin clot.7 These events occur alongside primary
hemostasis, but rather than facilitating platelet aggregation,
they induce the formation of an insoluble fibrin clot through
the binding of the pro-coagulant tissue factor (TF) molecule
to coagulation factor fVII, forming a TF/fVII complex that
can cleave factorX into factorXa, a molecule that generates
thrombin. Thrombin activates the adherent platelet aggre-
gate, allowing several other pro-coagulant factors to bind
to the surface of the aggregate. Thrombin also activates
fibrinogen, which in turn produces a cross-linked fibrin
mesh. Platelet activation also results in an increase of
GPIIb-IIIa, a platelet surface integrin that serves as a recep-
tor for fibrinogen and carries out mediated fibrinogen bind-
ing during the fibrin-platelet crosslinking process.10,12 The
fibrin mesh and platelet aggregate form a complete clot that
can prevent further blood loss.7,13
Following the cessation of bleeding, cytoplasmic motility
proteins, including actin and myosin, facilitate platelet clot
contraction, resulting in expulsion of serum from the clot.14
The contractile forces generated by the platelet-rich plasma
within the clot increases with time, forming a seal at the clot
site to fortify the hemostatic capabilities of the clot. Local
fibrin concentration and clot stiffness increase as clot con-
traction occurs over time; therefore, it is likely that platelets
actively increase their contractile forces in response to the
changing fibrin dynamics over time. Indeed, atomic force
microscopy experiments with single platelets attached to
fibrinogen-coated surfaces demonstrate that force gener-
ation by individual platelets increases in response to
increased cantilever stiffness.15 Additionally, platelets
become increasingly activated on increasingly stiff fibrino-
gen-coated surfaces.16 Clot contraction promotes wound
healing by decreasing the clot surface area, which allows
greater blood flow to the healing tissue.14 Clot contraction is
supplemented by fibrinolysis, the process by which clots
are degraded, following contraction in order to prevent
thrombosis. Interestingly, clot retraction plays a role in the
dynamics of fibrinolysis, by increasing clot stability and
decreasing clot susceptibility to fibrinolysis.17,18
Platelets and the immune system
The unique structure and composition of platelets allow
them to interface with the immune system after injury by
targeting wound sites, facilitating healing, and preventing
infection or contamination from occurring at the site (Figure
1). Platelets are involved in several of the mechanisms com-
prising the first lines of defense against pathogenic sub-
stances in the body; circulating platelets have scavenger
receptors, including CD36, on their surfaces that constantly
scan the surrounding area for the presence of potentially
dangerous molecules or molecular patterns that could be
indicative of pathogenic activity.19 As part of the innate
immune system, platelets have a significant role in the
inflammatory response at sites of injury and/or disease
through activation of and close interaction with leukocytes
(regulated by cathepsin G), secretion of chemokines and
cytokines that attract other immune cells, and through add-
itional mechanisms that influence the body’s adaptive
immunity.10,20–23 Tissue inflammation and healing are
further modulated by protease-activated receptors (PARs)
found on platelet surfaces; these PARs stimulate the release
of alpha granules, which contain various growth factors
and angiogenic factors that aid in tissue repair.24,25 Many
glycoproteins found on the platelet surface membrane, such
as CD55 and CD59, are a part of the complement system,
which eliminates particulate invaders by providing recog-
nition mechanisms for phagocytes that can then clear inva-
ders from the body via phagocytosis.4 Other glycoprotein
receptors on the platelet surface membrane, such as
(GP)IIb-IIIa, GPIba, FcgRIIa, and toll-like receptors (TLRs),
are triggered when bacteria bind to the platelet surface;
these receptors, in turn, induce the secretion of antimicro-
bial peptides known as platelet microbicidal proteins,
which mediate chemotaxis of phagocytes, and cause the
platelet to shift from a quiescent to an activated
state.10,26,27 Additionally, TLRs are critical to thrombosis,
activation of the immune system cells, and determination
of both non-specific and specific immune responses to vari-
ous pathogens.28,29 Platelets also express Fc-receptors for
antibodies, which, together with the complement receptors,
allow them to bind virus-antibody complexes.30
Interactions between pathogens and platelet surface
receptors can trigger platelet activation and thrombus for-
mation. Bacterial binding can occur via direct or indirect
methods, including binding directly to a receptor on the
platelet’s surface, binding of secreted bacterial toxins to
platelet surface receptors, or binding to a plasma protein
that functions as a ligand for a platelet membrane recep-
tor.10 Platelets can also interface with viral particles as part
of the body’s immune response; however, in the case of
certain viral infections such as HIV, dengue virus, and hepa-
titis C, this interaction can result in the destruction of plate-
lets or platelet function and can lead to potentially fatal
levels of thrombocytopenia and bleeding.30,31
Despite the variety of capabilities that platelets possess
to fight pathogenic agents within the body, interactions
between platelets and pathogens can also create severe
problems for the immune system. For example, the throm-
botic response of platelets in the presence of bacteria can
lead to events such as strokes or pulmonary embolisms if
the thrombus forms on a heart valve. Even microthrombi
can present large problems if they result in blockade of the
body’s microvasculature.10 Additionally, in cancer patients,
the innate behavior of platelets that causes them to adhere
to pathogens and injured vasculature results in the aggre-
gation of platelets around tumor cells. This can have the
unintended effect of promoting tumor survival in the
bloodstream without creating a noticeable immune
response, allowing the tumor cells to metastasize and
extravasate to tissues or organs other than their tissue of
origin.32
The need for platelet-mimetic materials
As discussed in previous sections, several conditions, such
as traumatic injury, viral or bacterial infection, and chemo-
therapy, result in an insufficient number of natural platelets
to maintain hemostasis and innate immunity within the
body. The decrease in platelet levels within the body
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during viral infections can lead to severe and potentially
fatal bleeding, demonstrating the need for platelet-mimetic
materials for the treatment of diseases such as HIV and
Hepatitis C.30 In cases of traumatic injury, patients often
bleed out in the pre-hospital phase; therefore, platelet-
mimetic materials could provide sufficient stabilization in
traumatic injury victims to facilitate survival until hospital
care is received.33 In cancer patients, chemotherapy signifi-
cantly decreases platelet counts and often results in signifi-
cant bleeding problems, requiring multiple platelet
transfusions; these immunocompromised patients would
benefit greatly from synthetic platelet strategies.34,35
Platelet-mimetic materials could also improve targeted
drug delivery, since current targeting technologies are ham-
pered by nonspecific binding and insufficient margination
and circulation and thus cannot target specific molecules or
structures effectively.36 Since platelets have the ability to
marginate to the vascular wall, target injury sites, and can
effectively circulate throughout the body, the use of platelet-
mimetic technologies that mimic these features could allow
researchers and clinicians to more effectively deliver drugs
to specified locations within the body for improved thera-
peutic action. These agents could be used to treat bleeding
and hemorrhages, as well as thrombosis, atherosclerosis,
and cancer.
There are a wide variety of applications for platelet-
mimetic materials, and current strategies typically focus
on replicating various biochemical or mechanical properties
of platelets to replicate specific desired functions of natural
platelets, such as stabilization and augmentation of clot for-
mation (Figure 1).36–38 Current research in the field of plate-
let-mimetic technologies utilizes a wide variety of strategies
including both naturally derived platelet derivatives and
synthetic platelet strategies. In subsequent sections, we
review various strategies that encompass a large range of
approaches to achieve various goals such as wound target-
ing, drug delivery, and immune system evasion through
platelet membrane cloaking.
Platelet-mimetic strategies and technologies
Natural platelet derived approaches
Allogeneic platelet transfusion is the most commonly used
platelet therapy in the clinic. In clinical cases involving low
platelet counts, platelet transfusions are often used in order
to supplement or replace the activity of the body’s own
natural platelets.39 Platelet transfusion has the advantage
of utilizing natural platelets that innately possess the ability
to biologically, biochemically, and mechanically interface
with the immune system, endothelial cells, and other plate-
lets to the required degree to supplemental lost platelet
function, especially platelet functions required for hemosta-
sis. However, platelet transfusion is limited by the relative
lack of donors, storage cost, and short shelf life of donated
platelets, and the fact that most platelet therapy is done
prophylactically rather than therapeutically.40,41 The short
shelf life of stored platelets makes the development of new
therapeutic natural platelet-based technologies difficult.42
Even though recent technologies have improved the shelf
life of natural platelets to up to seven days, this shelf life
does not allow for a ‘‘bank’’ of platelets to be generated,
which may be necessary for therapeutic applications requir-
ing large volumes of platelets; furthermore, stored platelets
are placed at an increasing risk of bacterial contamination
that could result in a severe immunologic response if used
in a transfusion.43,44 Additionally, studies by Ponschab
et al.44 demonstrated that platelets increasingly lose their
ability to aggregate over the short period of time in which
they are kept in storage, further complicating the use of
natural platelets as a viable means of treatment for vascular
injury or disease. Platelet transfusion also has the inherent
risk of transmission of blood-borne diseases; polymorph-
ism of human platelet antigen (HPA) and human leukocyte
antigen (HLA) after transfusion can also lead to complica-
tions such as transfusion refractoriness, which is the failure
to achieve the desired level of platelets following transfu-
sion, and von Willebrand’s disease.22,43,45 Platelet transfu-
sion can also be potentially pro-inflammatory or highly
immunogenic; recipients of donated platelets run the risk
of alloimmunization, exposure to the transmission of infec-
tions, graft-vs-host disease, or transfusion-related immuno-
suppression, which could increase their vulnerability to a
host of other harmful pathogens.20,46
Therefore, the short shelf life of natural platelets poses a
considerable restriction on the practicality of platelet trans-
fusion therapy. This shortcoming is being combated
through the use of lyophilized platelets, which can be dehy-
drated and freeze-dried in order to improve the length of
their shelf life.46 Freeze-dried platelets can be prepared by
paraformaldehyde-treating platelets, washing in citrated
saline prior to freezing, and rehydrating in citrated saline
upon thawing. This freezing and thawing process allows
the lyophilized platelets to retain their hemostatic function-
ality, unlike previously investigated cryopreserved lyophi-
lized platelets washed in standard saline that were unable
to form the characteristic primary hemostatic platelet plug
after reconstitution.47 However, in vivo studies in animal
models indicate that these freeze-dried lyophilized plate-
lets, although capable of forming a hemostatic plug, have
a short duration of circulation, lasting only 9.5 min prior to
being cleared from the bloodstream.48 These lyophilized
platelets have also been shown to have the potential to
increase thrombogenicity and antigenicity, and aggregate
in the spleen.46 Therefore, the use of lyophilized platelets
lacks the reliability that is required for large scale clinical
application of naturally derived platelet replacements.
All platelet-substitute technologies utilizing donated
natural platelets, including transfusion and lyophilized
approaches, have a major drawback – introducing allogen-
eic platelets into the body can result in an immune response
that causes the recipient’s body to reject the donated plate-
lets, preventing them from addressing the injury or infec-
tion in question and further weakening the body as it
attempts to heal from an injury or fight harmful pathogens.
The risks of recipients developing adverse immune
responses can be minimized through blood-matching; how-
ever, blood-matching complicates this therapeutic strategy
by requiring clinicians to search through already limited
stores of platelets in an attempt to find a matched source,
making naturally derived platelet substitutes inefficient
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and unreliable for use in emergency trauma-related treat-
ments.45 As an alternative approach, studies performed by
Nguyen et al.24 demonstrated that the body’s existing plate-
lets can be differentially stimulated using the protease acti-
vated receptor agonists PAR-1-agonist and PAR-4-agonist
to selectively secrete VEGF, to promote angiogenesis, or
endostatin, an anti-angiogenic factor. While the conclusions
they drew from this study need to be tested under more
applicable physiological conditions, such as in the presence
of microbial agents, this method may present a useful
Figure 2 Synthesis and analysis of platelet-like nanoparticles developed by Anselmo et al.36 (a) schematic and (b) scanning electron microscope images of layer-by-
layer synthesis of nanoparticles using alternating layers of bovine serum albumin and poly(allylamine hydrochloride) (PAH) and a degraded core to achieve deformable
particles with platelet-like discoid morphology. Scale bars¼ 200nm. (c) Percentage of surface area coverage of ovalbumin-coated spherical particles of various sizes;
(d) Percentage of surface area bound by platelet-like nanoparticles in comparison with ovalbumin-coated particles bound by larger spherical or discoid particles. Scale
bars¼20 nm. This is an unofficial adaptation of an article that appeared in an ACS publication. ACS has not endorsed the content of this adaptation or the context of its
use. Reproduced from (Anselmo AC, Modery-Pawlowski CL, Menegatti S, Kumar S, Vogus DR, Tian LL, Chen M, Squires TM, Sen Gupta A, Mitragotri S. Platelet-like
nanoparticles: mimicking shape, flexibility, and surface biology of platelets to target vascular injuries. ACS Nano 2014 25;8:11243–53.) (A color version of this figure is
available in the online journal.)
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future method of utilizing natural platelets and their exist-
ing immunological and healing mechanisms on an ampli-
fied scale without the need for platelet transfusions.
Artificial platelets
Artificial platelet-mimetic technologies address the
immunogenicity issues raised by natural platelet-based
treatments, because artificial materials do not need to be
blood-matched prior to therapeutic use, but must still be
evaluated for biocompatibility and other potential adverse
effects, such as thrombotic responses.49 The use of artificial
platelet-mimetic materials prevents adverse immune
responses from developing within the body as well as
decreases clearance of targeted therapeutic nanoparticles
from the bloodstream. Clearance of nanoparticle-based
technologies is low because they are generally not
recognized or marked by the immune system, and clear-
ance can be further modified through nanoparticle size or
material parameters.36,50 Synthetic materials have further
advantages over natural platelets due to their longer shelf
life, scale-up potential, and ease of manufacturing and
reproducibility.3 The material properties of artificial plate-
let-mimetic devices can also be tuned to reflect the mech-
anical properties of natural platelets in both their resting
and active conformations, giving researchers a greater
level of control over obtaining specific desirable character-
istics, such as clearance time, for various particular clinical
applications.
A multitude of design strategies have been utilized to
create artificial platelets and typically entail the coupling
of a particle or polymer platform with a binding motif
that facilitates interactions at a wound site (Figure 1).
Particle platforms previously utilized for artificial platelets
have included liposomes, albumin microparticles, latex par-
ticles, and even erythrocytes.3 Wound targeting strategies
vary widely and having included targeting elements which
bind to the subendothelial matrix, platelets, both the
subendothelial matrix and platelets, and fibrin. Examples
include coupling of full-length fibrinogen, fibrinogen-
derived RGD-peptides and other fibrinogen-mimetic pep-
tides, platelet surface glycoproteins, and fibrin-specific
single domain variable fragment antibodies (sdFvs). Past
and state-of-the art strategies to create artificial platelets
have been reviewed in detail by others recently.3,51,52
Several recent attempts to develop artificial platelet technol-
ogies have focused on designing particles capable of
mimicking the shape and mechanical properties of natural
platelets; we primarily focus this review on such attempts.
Platelets are generally found in the bloodstream in their
inactive, or quiescent, state, and only shift to their active,
spread conformation in the presence of an injury or patho-
gen.36 Attempts to mimic natural platelet shape and mech-
anics could potentially lead to particles that are capable of
replicating the shape change of natural platelets following
activation. Efforts in this area include the creation of par-
ticles capable of mimicking the mechanical properties of
active platelets, then coupling with various binding
agents to confer specificity for molecules present in active
wound sites.11,36,38 Doshi et al.11 formed synthetic platelet-
like particles by stretching polymeric particles into a discoid
shape reminiscent of the true shape of natural platelets,
crosslinking alternating layers of bovine serum albumin
and polyelectrolytes over the stretched discoid particles,
then degrading the polymeric core to leave a flexible dis-
coid capable of imitating the mechanical stretching of
natural platelets.11 Anselmo et al.36 also made use of a
layer-by-layer synthesis method with a degraded core to
imitate innate platelet deformability while synthesizing their
own platelet-like nanoparticles (Figure 2).36 In an alternative
approach, Brown et al.38,53 used soft pNIPAM-based micro-
gels synthesized via precipitation polymerization to yield
ultra-low cross-linked particles with a high degree of flexibil-
ity that allow for extensive spreading within fibrin clots.
Following structural design development, platelet-like
particles with appropriate mechanical properties can be
functionalized with various molecules to confer targeting
Figure 3 Structure and behavior of platelet-like particles developed by Brown
et al. (a) Schematic of natural platelet behavior mimicked by platelet-like particles
during clot formation and collapse. (b) Schematic of the structure of the platelet-
like particles; ultra-low cross-linked pNIPAM-based microgels are coupled to H6
sdFvs to confer fibrin specificity. (c) In silico demonstration of clot collapse
induced by platelet-like particles. Reprinted by permission from Macmillan
Publishers Ltd: [Nature Materials] (Brown AC, Stabenfeldt SE, Ahn B, Hannan RT,
Dhada KS, Herman ES, Stefanelli V, Guzzetta N, Alexeev A, Lam WA, Lyon LA,
Barker TH. Ultrasoft microgels displaying emergent platelet-like behaviours. Nat
Mater 2014;13:1108–14.), copyright (2014). (A color version of this figure is
available in the online journal.)
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capabilities onto the particle surface. This can be done via a
variety of targeting methods, including peptides, antibo-
dies, and growth factors. Doshi et al.11 conferred targeting
abilities to their particles via the VWF-A1 domain or
GPIbaN (an amino terminal domain of GPIba), which
resulted in particles that adhere to injured endothelial vas-
cular walls under high shear stress, and to each other to
form an aggregate at the injury site. Particles synthesized
by Anselmo et al.36 were heteromultivalently surface-deco-
rated with peptides to give them binding specificity for
exposed collagen and VWF in the vascular injury site and
GPIIb-IIIa on activated natural platelets. This method
allows for simultaneous targeting of the wound site and
aggregation of platelets to each other, increasing the efficacy
of the particles in targeting wound sites and decreasing
bleeding time. A study performed by Ravikumar et al.54,55
also involved particles surface-decorated with VWF and
collagen-binding ligands, with the purpose of promoting
binding to VWF under shear flow and binding to collagen
independent of shear flow in order to imitate the dual-bind-
ing adhesion and aggregation capability of natural platelets.
The platelet-like particles developed by Brown et al.38 use
sdFvs, identified through phage display techniques, to
obtain a high specificity for fibrin, allowing the particles
to target fibrin clots, and therefore secondary hemostasis
(Figure 3). These platelet-like particles were found to
spread within the fibrin network, and induce collapse of
the fibrin network, without binding fibrinogen present in
the blood stream or in areas without injured vasculature.
The particle-mediated clot collapse was found to be
dependent on the deformability of the particles coupled
with high affinity for fibrin, conferred by the sdFv.38
Fibrin monomers cleaved from fibrinogen by thrombin
enzymes also possess the ability to self-polymerize and
assemble into a three-dimensional scaffold.
Transglutaminase factor XIIIa supplements the scaffold by
increasing the fiber density and helps to stabilize the clot by
creating crosslinks between the fibers.56 Pun and her co-
workers developed a synthetic hemostatic polymer
known as PolySTAT that mimics the crosslinking behavior
of factor XIIIa to stabilize clots and inhibit fibrinolysis via
incorporation of polymers that are resistant to plasmin
enzyme degradation (Figure 4). PolySTAT was synthesized
from poly(HEMA) copolymerized with NHSMA mono-
mers to create a polymer capable of a high degree of peptide
grafting. Once inserted into the body, PolySTAT bound
noncovalently to fibrin monomers to strengthen clots.
Haji-Valizadeh et al.8 developed an alternative strategy for
creating artificial platelets, involving the use of self-
assembled peptide-lipid nanoconstructs that can adhere to
injury sites and facilitate aggregation of active platelets. The
nanoconstructs were coated in a factor FVIII-VWF binding
peptide that was able to promote the injury-site adhesion
component of the design, while additional fibrinogen-
mimetic peptides on the nanoconstruct surface functioned
to promote platelet aggregation. The use of the factor FVIII-
VWF binding peptide allowed the nanovehicles to target
and bind to injury sites without obstructing the binding
mechanisms of natural platelets, which resulted in a greater
degree of overall aggregation than was possible with the
synthetic or natural platelets alone.8 Overall, these recent
approaches have resulted in platelet-mimetics that more
closely recapitulate natural platelet mechanics and shape.
Cloaking and active targetingmechanisms for
drug delivery
Platelet technology also has potential applications in the
field of targeted drug delivery. The concept of ‘‘pairing’’ a
drug delivery vehicle with native cells can be illustrated
within the natural interactions of the immune system, as
platelets’ endothelial cell adhesion molecules often bind
to antibodies to increase the efficacy of both components
in binding to their targets in the injured vascular endothe-
lium.57 The discoidal shape of platelets also makes them a
prime candidate for providing cloaking mechanisms to
drug delivery particles, since more discoidal particles
tend to marginate to vessel walls under shear flow, allowing
specific targeting of injured vascular sites.58 Platelet
Figure 4 Schematics and scanning electron microscope images of in vitro PolySTAT-induced fibrin clots. Fibrin clots showed binding specificity for PolySTAT over
PBS and scrambled nonbinding polymer PolySCRAM. PolySTAT induced clot formation through fibrin crosslinking in a manner reminiscent of natural factor XIIIa-
induced crosslinking. Scale bars¼250nm. From (Chan LW, Wang X, Wei H, Pozzo LD, White NJ, Pun SH. A synthetic fibrin cross-linking polymer for modulating clot
properties and inducing hemostasis. Sci Transl Med 2015;7:277ra29.). Reprinted with permission from AAAS. (A color version of this figure is available in the online
journal.)
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membrane-cloaked nanoparticles can be used in a similar
manner to deliver drugs to specific structures, such as
wound sites or thrombi, in the body without causing a
severe immune response, which could prevent the drug
capsules from being delivered effectively. This membrane-
encapsulated strategy allows for greater circulation time,
since high clearance rates are often a hindrance to effect-
ively targeted drug delivery, decreased immunogenicity,
and improved specific targeting.59 Cloaked drug delivery
can also suppress the complement system, increasing the
Figure 5 (a) Schematic of platelet membrane-enclosed nanovehicle drug delivery mechanism developed by Hu et al.59 Platelet membranes are isolated via cen-
trifugation and then used to enclose the doxorubicin-nanovehicle particle. Themembrane-doxorubicin-nanovehicle particle is loaded with TNF-related apoptosis ligand
(TRAIL) and inserted into the bloodstream, where it can target and deliver doxorubicin and TRAIL to circulating tumor cells. Reprinted by permission from Wiley (Hu Q,
SunW, Qian C, Wang C, Bomba HN, Gu Z. Anticancer platelet-mimicking nanovehicles. Adv Mater 2015 September). (b) Drug delivery vehicle developed by Hu et al.,32
in which PLGA nanoparticles are enclosed in platelet membranes obtained via centrifugation to confer immunocompatibility and targeting specificity for injured vascular
endothelium to the PLGA nanoparticles. Reprinted by permission from MacMillan Publishers Ltd: [Nature] (Hu C-MJ, Fang RH, Wang K-C, Luk BT, Thamphiwatana S,
Dehaini D, Nguyen P, Angsantikul P, Wen C, Kroll A, Carpenter C, Ramesh M, Qu V, Patel S, Zhu J, Shi W, Hofman F, Chen C, Gao W, Zhang K, Chien S, Zhang L.
Nanoparticle biointerfacing by platelet membrane cloaking. Nature 2015 September 16;526:118–21.), copyright (2015). (A color version of this figure is available in the
online journal.)
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antimicrobial efficacy of the system, and has several poten-
tial applications in the field of cancer nanomedicine due to
the natural aggregation of platelets around metastatic
tumors.32,59,60
The Gu research group has developed a platform for
delivering anticancer drugs within a platelet membrane-
enclosed nanovehicle (Figure 5(a)). The outer platelet mem-
brane shell of the particle is coated with proteins such as
P-selectin, which allow the particle to bind CD44 receptors
on cancer cells, and the inner nanogel is loaded with doxo-
rubicin, a small-molecule anticancer drug that can be
released upon internalization and subsequent digestion of
the particle by cancer cells.59 In vivo testing of the particles
in MDA-MB-231 tumor-bearing mice revealed that the par-
ticles exhibit significant antitumor effects with minimal
immunogenicity.59 Hu et al.32 developed a nanoparticle
drug delivery system cloaked in platelet plasma
membranes to reduce clearance of the nanovehicles by
macrophages in the immune system (Figure 5(b)).32 In
their design, polymeric nanoparticles were loaded with
drugs and enclosed in platelet plasma membranes that
had previously been treated to remove thrombotic mol-
ecules, thus decreasing the chance of an immune response
when inserted into the body.32
Alternative methods of active targeting involve nano-
constructs that have been surface-decorated with various
peptides or ligands that can bind to areas on active platelets,
injured vessel walls, or cancer cells. Modery et al.61 devel-
oped a platform for targeting injury sites using surface-
decorated nanoconstructs. The nanoconstructs are coated
with peptides that have a high affinity for GPIIb-IIIa and
P-selectin, which bind active platelets in sites of vascular
disease or injury. These peptides allow the nanoconstructs
to target specific wound sites with a high level of specificity
and release thrombolytic or anti-proliferative therapeutic
drugs at sites of injury, thrombosis, or vascular disease
such as atherosclerosis.61 Similar heteromultivalent
ligand-receptor pathway surface-decorated nanoconstructs
were later used by this group to target and deliver antic-
ancer drugs to metastatic MDA-MB-231 and MCF-7 cancer
cells (Figure 6).37
Conclusion
Platelets have a multitude of functions in addition to their
vital role in coagulation and hemostasis, including modu-
lating immune functions through interactions with patho-
gens and cytokine and growth factor release, immune
cloaking, and modulation of cancer metastasis. The design
of platelet mimetic technologies has shown promise for
augmentation of hemostasis following traumatic injury, tar-
geted delivery of cancer therapeutics, and improved immu-
nocompatibility of nanoparticle platforms. As researchers
continue to develop more sophisticated strategies for
mimicking platelet features and functions, and as we
learn more about platelet biology, we can likely expect to
continue to see additional application of artificial platelet
technologies. Thus, while artificial platelet technologies
emerged in an effort to merely supplement the hemostatic
function of platelets, the potential application of artificial
platelet technologies clearly extends into numerous
additional areas including targeted drug delivery, cancer
therapeutics and immune modulation.
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